FDA Panel Votes Against Approving Regeneron's Gout Drug
A U.S. Food and Drug Administration advisory panel voted unanimously against recommending approval of Regeneron Pharmaceuticals Inc.'s drug Arcalyst for gout flares Tuesday, with committee members saying they'd want to see...To view the full article, register now.
Already a subscriber? Click here to view full article